Body Composition and Side Effects in Lung Cancer Patients on Carboplatin
Studies whether body makeup relates to side effects in adults with advanced lung cancer.
Plain-language title generated from the registry record
Registry title: Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced NSCLC
Key facts
- Where
- Mexico City, MexicoSee the site
Where in Mexico
- Instituto Nacional de CancerologiaMexico City, MexicoTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Instituto Nacional de Cancerologia de Mexico
- Trial code
- NCT02734069
- Record updated
- 24 December 2025
- Original description
This study evaluate the association of body composition (mainly free-fat mass), clinical and biochemical parameters with development of toxicity in patients under treatment with Carboplatin/Paclitaxel in advanced NSCLC.Read full original descriptionShow less
Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
This study evaluate the association of body composition (mainly free-fat mass), clinical and biochemical parameters with development of toxicity in patients under treatment with Carboplatin/Paclitaxel in advanced NSCLC.
Inclusion: Diagnosis of NSCLC Stage IV (stratification according to the American Joint Committee on Cancers - 7th edition); Candidates for treatment with carboplatin plus paclitaxel 1st line; Performance status (ECOG 0-2); Laboratory studies that demonstrate adequate renal, hepatic and hematologic function (blood chemistry and blood count); Normal renal ultrasound prior to initiation of treatment.
Exclusion: Patients with renal impairment (KDOQI 3-5); Uncontrolled diabetes (> 130 mg / dL); Patients who do not have computed tomography study at baseline; Uncontrolled blood pressure (> 140 mmHg); Obstruction in kidney (s) or ureter (s); Dehydrated patients; Patients with high consumption of NSAIDs (aspirin, ibuprofen, etc.> 1 month).